A woman with advanced Alzheimer's disease experienced temporary functional improvements after a high-dose psilocybin mushroom session. Digest
Alzheimer's disease gradually erodes memory, language, and independence, leaving few treatment options once the condition becomes severe. Researchers explored whether psilocybin, a naturally occurring psychedelic compound in certain mushrooms, could affect abilities that had been severely impaired for years.
You just missed this in your inbox
Every other week our Premium Members received this exact study plus Rhonda's practical commentary and 8+ other hand-picked papers.
The case report focused on one Japanese-American woman in her 80s with a clinical diagnosis of advanced Alzheimer's disease and about 10 years of progressive decline. For about five years before the intervention, she had mostly one-word replies, long-term loss of bladder control, difficulty walking without help, swallowing problems, flat emotional expression, and high dependence in daily activities. She received a supervised 5-gram oral dose of psilocybin-containing mushrooms, followed one month later by a supervised 3-gram session. Changes in her condition were described through clinical observations rather than formal cognitive tests, brain scans, lab measures, or sleep monitoring.
- Speech improved in a striking way. After years of mostly one-word replies, the woman began talking spontaneously about her past roughly 19 hours after the first dose. This period of autobiographical conversation lasted about four hours.
- After years of chronic incontinence, bladder control returned within days of the first session and persisted for at least one month.
- In the week following the session, she also became more alert, recognized family members, was able to walk without assistance, dressed herself, showed more initiative, and engaged more socially through eye contact, smiling, and responses that showed awareness of people, surroundings, and social context.
- After the second psilocybin session, the woman was described as more verbally expressive, emotionally responsive, humorous, and agile while walking.
- The first session also came with some short-term safety concerns. In the first 12 hours, she experienced suspected overheating, heavy sweating, and a prolonged sleep-like state. However, no severe lasting complications were reported.
Psilocybin is converted in the body to psilocin, which activates serotonin receptors in the brain. That activation can make brain activity less locked into its usual patterns, allowing networks involved in memory, attention, emotion, and self-awareness to interact in less rigid ways. At the cellular level, psychedelics can also trigger plasticity-related programs that help neurons remodel connections between nerve cells. In advanced Alzheimer's disease, these effects would not rebuild lost brain tissue or remove the underlying disease process. A more plausible explanation is that psilocybin may temporarily alter access to still-surviving circuits that were no longer being used effectively.
This was a single uncontrolled case, so it cannot prove efficacy or safety of psilocybin for people with Alzheimer's disease. However, the observations raise the possibility that psilocybin may temporarily restore access to some abilities that appear lost in advanced dementia. In episode #30, the late Dr. Roland Griffiths discusses the effects of psilocybin on the human brain.